– SWITZERLAND, Root – Novocure (NASDAQ: NVCR) today announced the election of Dr. Allyson Ocean (M.D.) to its Board of Directors.
“We are honored to welcome Dr. Ocean to our board of directors,” said William Doyle, Novocure’s Executive Chairman. “With her extensive expertise in gastrointestinal oncology and as a practicing clinician, Dr. Ocean will provide important insights and guidance as we strive to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy.”
About Dr. Allyson J. Ocean
Dr. Allyson Ocean is an internationally recognized academic gastrointestinal medical oncologist specializing in translational and clinical research, the development of novel therapeutics, and patient advocacy.
Dr. Ocean is an Associate Professor of Clinical Medicine at Weill Cornell Medicine, where she has worked since 2004.
Dr. Ocean is co-founder and Scientific Advisory Board Chair of Let’s Win Pancreatic Cancer, an award-winning non-profit organization missioned to increase access to treatment options and clinical trials for patients with pancreatic cancer. Let’s Win received the inaugural Biden Cancer Initiative FIERCE Award for Leadership through Exemplary and Awesome Purpose for its transformative impact on the lives of cancer patients. Additionally, Dr. Ocean serves on several scientific advisory boards. She is the author of numerous peer-reviewed articles and abstracts and is an active member of several professional societies, including the American Society of Clinical Oncology and the American Association for Cancer Research.
“I look forward to working with the esteemed individuals on Novocure’s board to advance our mission to help patients who currently have limited treatment options,” said Dr. Allison Ocean. “As a clinician, I understand what these patients go through every day. The reality of cancer therapy is that many treatments are poorly tolerated and have harsh side effects even when effective. Through science, we can deliver better treatments to more patients.”
Dr. Ocean graduated cum laude from Tufts University and received her M.D. with AOA honors from the Tufts University School of Medicine.
About Novocure
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for treating adult patients with glioblastoma, malignant pleural mesothelioma, and pleural mesothelioma. Novocure has ongoing or completed clinical studies investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
Headquartered in Root, Switzerland, and with a growing global footprint, Novocure has regional operating centers in Portsmouth, New Hampshire, and Toky and a research center in Haifa, Israel.
For more information: https://www.novocure.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
